Behavioral Diagnostics

Behavioral Diagnostics is a private, commercial-stage diagnostics company pioneering epigenetic tests for behavioral health and oncology risk stratification. Its technology platform analyzes DNA methylation patterns from blood or saliva to objectively quantify smoking and alcohol consumption, and to assess personalized lung cancer risk, addressing significant gaps in self-reported data and preventive screening. The company targets multiple customer segments including healthcare providers, insurers, employers, and direct-to-consumer patients, positioning its tests as tools for shared decision-making, underwriting, workplace wellness, and personal health monitoring. Backed by NIH-funded research and a deep product pipeline, it aims to revolutionize early detection and preventive care.

Precision epigenetics platform analyzing DNA methylation patterns from blood/saliva, combined with artificial intelligence, to quantify environmental exposures (smoking, alcohol) and assess disease risk.

Claims to have 'no close competitors' for its specific epigenetic signatures for smoking and alcohol. However, operates in broader competitive spaces: lung cancer risk assessment (e.g., other liquid biopsy companies), and substance use testing (traditional urine/blood tests, breathalyzers). Differentiation lies in the objective, long-term measure of exposure via DNA methylation that is resistant to short-term abstinence.